Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Idec Gains EU Approval for Avonex Pen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Biogen Idec Gains EU Approval for Avonex Pen

Biogen Idec received approval from the European Commission for its Avonex Pen for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec received approval from the European Commission for its Avonex Pen for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event.

Avonex Pen is the first single-use, once-a-week, integrated intramuscular autoinjector available for use with Avonex treatment in patients with relapsing MS. The company designed Avonex Pen to improve convenience of administration by simplifying the injection and supporting patient independence.

“At Biogen Idec, our commitment to the MS community is unwavering. We strive to meet the needs of all MS patients by harnessing our extensive expertise in neurology and through our commitment to research and innovation,” said Douglas E. Williams, Ph.D., executive vice president, R&D at Biogen Idec. “For more than 10 years, Avonex has been the therapy of choice for many MS patients who prefer the convenience of once-weekly injections, along with its proven efficacy and a well-established safety profile. Not only do we think Avonex Pen makes Avonex therapy more convenient, it can also help alleviate the anxiety that some MS patients feel when they have to inject their medication.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters